Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio backfire – Endpoints News

Posted: July 1, 2020 at 12:57 pm

You dont go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a promotional press release. And Inovio captures the prize in baiting the hook.

Tuesday morning Inovio, which has been struggling to get its Covid-19 vaccine lined up for mass manufacturing, put out a release that touched on virtually every hot button in pandemic PR.

There was, first and foremost, an interim snapshot of efficacy from their Phase I program for INO-4800.

Analyses to date have shown that 94% (34 out of 36 total trial participants) demonstrated overall immunological response rates based on preliminary data assessing humoral (binding and neutralizing) and T cell immune responses.

Moderna was criticized for its decision to sketch initial antibody responses which it said were at or above the level needed to guard against the pandemic at 2 doses over various times. But it provided a treasure of information compared to Inovios barebones explanation. The full data set, Inovio says, will be published later in a peer-reviewed journal. In the meantime, theyre largely leaving the data readout to the reader to decipher.

Also dangling bait to day traders:

A Phase II/III study should be set to go this summer, if regulators sign off. Plus, Operation Warp Speed the presidents initiative at achieving a vaccine rollout, around the election is including 4800 in a non-human primate study. And then there was the trusty mouse study, in which their vaccine prevented viral replication in rodent lungs after the tiny creatures were challenged with SARS-CoV-2.

Usually, that sort of release delivers a powerful if temporary surge in the share price. But this morning, Wall Street proved skeptical.

Inovios stock price slid 11% as some experienced observers called them out.

Inovios attempt to break out of the pack seemed to largely backfire this morning. When youre in a race involving AstraZeneca, Pfizer, Moderna, a host of Chinese companies, and many, many more, it seems the usual bait doesnt work so well.

Here is the original post:
Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio backfire - Endpoints News

Related Post

Comments are closed.

Archives